Prelude Therapeutics Incorporated (PRLD)
Automate Your Wheel Strategy on PRLD
With Tiblio's Option Bot, you can configure your own wheel strategy including PRLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRLD
- Rev/Share 0.0921
- Book/Share 0.9979
- PB 1.5532
- Debt/Equity 0.2363
- CurrentRatio 3.6769
- ROIC -1.3958
- MktCap 85535738.0
- FreeCF/Share -1.4281
- PFCF -0.7881
- PE -0.9475
- Debt/Assets 0.1559
- DivYield 0
- ROE -1.065
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PRLD | H.C. Wainwright | Neutral | Buy | -- | $5 | Sept. 19, 2024 |
News
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Published: November 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (NASDAQ: PRLD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prelude Therapeutics Incorporated ("Prelude" or the "Company") (NASDAQ: PRLD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (NASDAQ: PRLD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Read More
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.
Read More
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Prelude Therapeutics (PRLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Prelude Therapeutics Incorporated (PRLD)
- IPO Date 2020-09-25
- Website https://www.preludetx.com
- Industry Biotechnology
- CEO Krishna Vaddi
- Employees 131